Medical Management of Chronic Myelogenous Leukemia (Basic and Clinical Oncology) - Tapa dura

"Coedited by the lead investigator of new drug trials for STI571, a new treatment for chronic myelogenous leukemia. Reported during the December, 2000 meeting of the American Society of Hematology, San Francisco, California, Dr. Talpaz called the pill the holy grail we are looking for in our business. this clinically-oriented book provides an excellent overview of the current medical management of CML at the turn of the century. It also provides information to understand the basis of some of the novel therapeutic modalities, which will reach clinical trials in the near future.highly recommended to all physicians dealing with CML. "-Annals of Oncology

This valuable reference provides a timely summary of current therapies for chronic myelogenous leukemia (CML), discussing both basic pathophysiology and new experimental strategies.
Combining the insights of over 30 prominent researchers in the field, Medical Management of Chronic Myelogenous Leukemia

compares interferon therapy with conventional chemotherapy

covers chronic, accelerated, and Philadelphia-negative phases

details standard therapy with IFN- regimens and allogenic stem cell transplantation

describes the utility and limitations of CML animal models

profiles clinical trials testing IFN in combination with other agents

assesses improvements in survival times among CML patients

reviews the effectiveness of Southern blot monitoring

traces the development of oligonucleotides as potential therapeutic agents

outlines therapy with monoclonal antibodies, targeted NK cells, and immune T cells

and more!
Containing over 1500 references, tables, drawings, and photographs, Medical Management of Chronic Myelogenous Leukemia is suitable for clinical oncologists, hematologists, immunologists and researchers in the fields of tumor immunology and cancer immunotherapy, internists, and residents, fellows, and medical school students in these disciplines.